N-(1,3-dimethyl-2-oxo-butyl)-acetamide | 101253-20-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(1,3-dimethyl-2-oxo-butyl)-acetamide
• 英文别名: 2-Acetylamino-4-methyl-pentan-3-on；N-(1,3-Dimethyl-2-oxo-butyl)-acetamid；N-(4-methyl-3-oxopentan-2-yl)acetamide
• CAS: 101253-20-7
• 化学式: C₈H₁₅NO₂
• 分子量: 157.213
• InChiKey: FRABQZFGHLJBAU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(1,3-dimethyl-2-oxo-butyl)-acetamide 在 盐酸 作用下， 生成 2-amino-4-methyl-3-pentanone
  参考文献：
  名称：

  Honjo et al., Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1955, vol. 75, p. 853

  摘要：

  DOI：
• 作为产物：
  描述：

  乙酸酐 、 4-methyl-pentane-2,3-dione 2-oxime 在 水 、 溶剂黄146 、 锌 作用下， 生成 N-(1,3-dimethyl-2-oxo-butyl)-acetamide
  参考文献：
  名称：

  Honjo et al., Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1955, vol. 75, p. 853

  摘要：

  DOI：

文献信息

• NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF
  申请人：Frost Lisa M.

  公开号：US20090281062A1

  公开（公告）日：2009-11-12

  The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure, ischemia/reperfusion injury and cancer.

  本发明涉及亚硝基衍生物，包括在生理条件下捐赠亚硝基（HNO）的羟基亚硝基化合物的羧酸和磷酸酯。发明中的化合物和组合物可用于治疗和/或预防对亚硝基疗法有响应的疾病或病症的发作和/或发展，包括心力衰竭、缺血/再灌注损伤和癌症。
• Novel Nitroso Compounds as Nitroxyl Donors and Methods of Use Thereof
  申请人：CARDIOXYL PHARMACEUTICALS, INC.

  公开号：US20130045951A1

  公开（公告）日：2013-02-21

  The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure, ischemia/reperfusion injury and cancer.

  本发明涉及一种亚硝基衍生物，包括羧酸和磷酸酯的羟基亚硝基化合物，可在生理条件下捐赠亚硝基（HNO）。该发明的化合物和组合物在治疗和/或预防对亚硝基疗法有反应的疾病或状况的发生和/或发展方面是有用的，包括心衰、缺血/再灌注损伤和癌症。
• Therapeutic Compounds and Their Use in Treating Diseases and Disorders
  申请人：Bajji Ashok C.

  公开号：US20100292255A1

  公开（公告）日：2010-11-18

  The invention provides novel therapeutic compounds, pharmaceutical compositions comprising these compounds, and methods for using these compounds and compositions to treat diseases and disorders, such as cancer.

  该发明提供了新型治疗化合物、包含这些化合物的药物组合物以及使用这些化合物和组合物治疗疾病和疾病的方法，例如癌症。
• Benzimidazole derivatives
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US10752611B2

  公开（公告）日：2020-08-25

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式（I）化合物或其药学上可接受的盐、酯或原药： 它们能抑制含 RNA 的病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物可干扰丙型肝炎病毒的生命周期，也可用作抗病毒药物。本发明进一步涉及包含上述化合物的药物组合物，用于给丙型肝炎病毒感染者用药。本发明还涉及通过施用包含本发明化合物的药物组合物治疗受试者感染 HCV 的方法。
• HEPATITIS C VIRUS INHIBITORS
  申请人：Or Yat Sun

  公开号：US20100260715A1

  公开（公告）日：2010-10-14

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.